ALTG 10/001 TROG 11.03 PLUNG-GP: Randomised phase III trial of high dose palliative radiotherapy (HDPRT) vs concurrent chemotherapy and HDPRT (C-HDPRT) in patients with good performance status, locally advanced/small volume metastatic NSCLC not suitable for radical chemo-radiotherapy – M Lehman
The TROG 11.03 PLUNG-GP trial is a randomised Phase III trial comparing high dose palliative radiotherapy (HDPRT) with concurrent chemotherapy + HDPRT (C-HDPRT) in patients with good performance status, locally advanced or small volume metastatic NSCLC who are not suitable for radical chemo-radiotherapy, either due to tumour extent or patient factors. The optimal treatment approach for this group of patients is unknown and clinical practice varies throughout Australia. The PLUNG trial compares a widely employed high dose palliative radiotherapy regime (36Gy/12F) with a concurrent chemotherapy and high dose palliative radiotherapy regime (40Gy/20F + Vinorelbine + Cisplatin) which has been investigated in preceding Phase I and II trials conducted under the auspices of the Trans Tasman Radiation Oncology Group (TROG).
The objectives of the trial are to determine which regime is superior in terms of symptom relief and improvement in quality of life. The study has recruited 65 of the targeted 130 patients.
The study is open at Radiation Oncology Queensland (Toowoomba, Gold Coast and Cairns), Princess Alexandra Hospital, Royal Brisbane and Women’s Hospital, Townsville Hospital, Alan Walker Cancer Centre, Flinders Medical Centre, Peter MacCallum Cancer Centre, Calvary Mater Newcastle, Liverpool Hospital, Gosford Hospital and St George Hospital
Trial Chair: A/Prof Margot Lehman firstname.lastname@example.org
Trial Co-ordinator: Adrienne See, Princess Alexandra Hospital email@example.com